← Back to Clinical Trials
Recruiting NCT06605417

NCT06605417 Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06605417
Status Recruiting
Phase
Sponsor Fundacion Clinic per a la Recerca Biomédica
Condition Congenital Melanocytic Nevi
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-01-01
Primary Completion 2026-03-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
MethylomicsRNA sequencingSpatial transcriptomics

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-01-01 with a primary completion date of 2026-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are: * To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.

Eligibility Criteria

Inclusion criteria: * Congenital nevus with estimated size of 20 cm * Be over 18 years of age Exclusion criteria: * No available biological material * Not having signed the informed consent

Contact & Investigator

Central Contact

Susana Puig Sardà, MD, PhD

✉ spuig@clinic.cat

📞 +34932275400

Frequently Asked Questions

Who can join the NCT06605417 clinical trial?

This trial is open to participants of all sexes, studying Congenital Melanocytic Nevi. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06605417 currently recruiting?

Yes, NCT06605417 is actively recruiting participants. Contact the research team at spuig@clinic.cat for enrollment information.

Where is the NCT06605417 trial being conducted?

This trial is being conducted at Marseille, France, Barcelona, Spain.

Who is sponsoring the NCT06605417 clinical trial?

NCT06605417 is sponsored by Fundacion Clinic per a la Recerca Biomédica. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology